Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of tolfenamic acid, a non-steroidal anti-inflammatory drug (NSAID) with anticancer properties, and gemcitabine, a nucleoside metabolic inhibitor. Tolfenamic acid works through COX-independent mechanisms by degrading specificity protein transcription factors (Sp1, Sp3, and Sp4) and reducing VEGF expression, which inhibits tumor growth and angiogenesis. Gemcitabine is a cytidine analog that works by replacing building blocks of nucleic acids during DNA elongation, arresting tumor growth and promoting apoptosis of malignant cells. This combination is being investigated for the treatment of pancreatic cancer, particularly in combination with radiation therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tolfenamic acid + gemcitabine.